MDXG vs. XENT, CRY, ATEC, SIBN, OFIX, PRCT, AXNX, TNDM, IRTC, and NARI
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Intersect ENT (XENT), CryoLife (CRY), Alphatec (ATEC), SI-BONE (SIBN), Orthofix Medical (OFIX), PROCEPT BioRobotics (PRCT), Axonics (AXNX), Tandem Diabetes Care (TNDM), iRhythm Technologies (IRTC), and Inari Medical (NARI). These companies are all part of the "medical" sector.
Intersect ENT (NASDAQ:XENT) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.
MiMedx Group has higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, MiMedx Group had 2 more articles in the media than Intersect ENT. MarketBeat recorded 2 mentions for MiMedx Group and 0 mentions for Intersect ENT. MiMedx Group's average media sentiment score of 0.00 equaled Intersect ENT'saverage media sentiment score.
92.5% of Intersect ENT shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 2.1% of Intersect ENT shares are owned by insiders. Comparatively, 1.3% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
MiMedx Group has a consensus target price of $12.25, indicating a potential upside of 77.02%. Given Intersect ENT's higher probable upside, analysts plainly believe MiMedx Group is more favorable than Intersect ENT.
Intersect ENT received 371 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 77.78% of users gave MiMedx Group an outperform vote while only 60.15% of users gave Intersect ENT an outperform vote.
MiMedx Group has a net margin of 18.63% compared to MiMedx Group's net margin of -161.94%. Intersect ENT's return on equity of 39.42% beat MiMedx Group's return on equity.
Intersect ENT has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.
Summary
MiMedx Group beats Intersect ENT on 12 of the 16 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
